Classification, pathogenesis, and treatment of systemic vasculitis

Renal Failure

Volumn 18, Issue 5, 1996, Pages 785-802

  Griffith, Megan E ^a   Gaskin, Gillian ^a   Pusey, Charles D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; PREDNISOLONE;

ASEPTIC NECROSIS; AUTOIMMUNITY; BLADDER CANCER; CATARACT; CHRONIC OTITIS MEDIA; CHRONIC SINUSITIS; CLINICAL FEATURE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; GENETIC PREDISPOSITION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG HEMORRHAGE; MYELODYSPLASIA; PATHOGENESIS; PRIORITY JOURNAL; STRIDOR; SYSTEMIC VASCULITIS;

EID: 0029861266     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229609047707     Document Type: Conference Paper

References (119)

1. Godman GC, Churg J: Wegener's granulomatosis: pathology and review of the literature. Arch Pathol 58:533, 1954.
2. Hunder GG, Arend DA, Bloch DA, et al: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 33:1065-1136, 1990.
3. Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-192, 1994.
4. Couser WG: Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kid Dis 11:449-464, 1988.
5. Ferrario F, Tadros MT, Napodano P, Sinico RA, Fellin G, D'Amico G: Critical re-evaluation of 41 cases of "idiopathic" crescentic glomerulonephritis. Clin Nephrol 41:1-9, 1994.
6. Angangco R, Thiru S, Esnault VLM, Short AK. Lockwood CM, Oliviera DBG: Does truly idiopathic crescentic glomerulonephritis exist? Nephrol Dial Transplant 9:630-636, 1994.
7. Andrews M, Edmunds M, Campbell A, Walls J, Feehally J: Systemic vasculitis in the 1980s - is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? J Roy Coll Phys 24:284-288, 1990.
8. Watts RA, Carruthers DM, Scott DGI: Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 25:28-34, 1995.
9. Hoffman GS, Kerr GS, Leavitt RY, et al: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488-498, 1992.
10. Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA: Ocular complications of Wegener's granulomatosis. Opthalmology 90:279-290, 1983.
11. Cameron JS: Renal vasculitis: microscopic polyartetitis and Wegener's granulomatosis. In Sessa A, Meroni M, Battini G. (eds.), Renal Involvement in Systemic Vasculitis. Basel, Karger, 1991, pp 38-46.
12. Bindi P, Mougenot B, Mentre F, et al: Necrotizing crescentic glomerulonephritis without significant immune deposits: a clinical and serological study. Q J Med 86:55-68, 1993.
13. Luqmani RA, Bacon PA, Beaman M, et al: Classical versus nonrenal Wegener's granulomatosis. Q J Med 87:161-167, 1994.
14. Gaskin G, Pusey CD: Systemic vasculitis. In Davison AM, Cameron JS, Grunfeld JP, Kerr DNS, Ritz E (eds), Oxford Textbook of Clinical Nephrology. Oxford, Oxford University Press, 1996, in press.
15. Bosch X, Lopz-Soto A, Mirapeix E, Font J, Ingelmo M, Urbano-Marquez A. Antineutrophil cytoplasmic antibody-associated alveolar capillaritis in patients presenting with pulmonary haemorrhage. Arch Pathol Lab Med 118:517-522, 1994.
16. Gaskin G, Griffith ME, Lumley J, Pusey CD: Severe alveolar haemorhage in primary systemic vasculitis. Clin Exp Immunol 101:65, 1995.
17. Davies DJ, Moran JE, Niall JF, Ryan GB: Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J 285:606, 1982.
18. van der Woude FJ, Rasmussen N, Lobatto S, et al: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet i:425-429, 1985.
19. Savage COS, Winearls CG, Jones S, Marshall PD, Lockwood CM: Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet i:1389-1393, 1987.
20. Hagen EC, Ballieux BE, van Es LA, Daha MR, van der Woude FJ: Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences [review]. Blood 81:1996-2002, 1993.
21. Goldschmeding R, van der School CE, ten Bokkel Humink D, et al: Wegener's granulomatosis autoantibodies identify a novel diisopropylftuorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 84:1577-1587, 1989.
22. Niles JL, McCluskey RT, Ahmad MF, Amin Amaout M: Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 74:1888-1893, 1989.
23. Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318:1651-1657, 1988.
24. Knudson BB, Joergensen T, Munch-Jensen B: Wegener's granulomatosis in a family. Scand J Rheumatol 17:225-227, 1988.
25. Muniain M, Moreno J, Campora RG: Wegener's granulomatosis in two sisters. Ann Rheum Dis 45:417-421, 1986
26. Franssen CFM, Ter Maaten JC, Hoorntje SJ: Brother and sister with myeloperoxidase associated autoimmune disease. Ann Rheum Dis 53:213, 1994.
27. Katz P, Ailing DW, Haynes BF, Fauci AS: Association of Wegener's granulomatosis with HLA-B8. Clin Immunol Immunopathol 14:268-270, 1979.
28. Elkon KB, Sutherland DC, Rees AJ, Hughes GRV, Batchelor JR: HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. Arthritis Rheum 26:102-105, 1983.
29. Muller GA, Gebhardt M, Kompf J, Baldwin WM, Ziegenhagen D, Bohle A: Association between rapidly progressive glomerulonephritis and the properdin factor BfF and different HLA-D region products. Kidney Int 25:115-118, 1984.
30. Hagen EC, Stegeman CA, D'Amaro J, et al: Decreased frequency of HLA DR6/DR13 in patients with Wegener's granulomatosis. Clin Exp Immunol 101 (suppl 1): 55, 1995.
31. Spencer SJW, Burns A, Gaskin G, Pusey CD, Rees AJ: HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int 41:1059-1063, 1992.
32. Zhang L, Jayne D, Zhao MH, Lockwood CM, Oliviera DBG: Distribution of MHC class II alleles in primary systemic vasculitis. Kidney Int 47:294-298, 1995.
33. Esnault VLM, Testa A, Aucrain M, et al: Alpha 1 antitrypsin genetic polymorphism in ANCA positive systemic vasculitis. Kidney Int 43:1329-1332, 1993.
34. Elzouki AN, Segelmark M, Wieslander J, Eriksson S: Strong links between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 236:543-548, 1994.
35. Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD: C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 11:438-443, 1996.
36. Finn JE, Zhang Li, Agrawal S, Jayne DRW, Oliviera DBG, Mathieson PW: Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant 9:1564-1567, 1994.
37. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al: Association between active Wegener's granu-lomatosis and anticytoplasmic antibodies. Arch Intern Med 149:2461-2465, 1989.
38. Pusey CD, Gaskin G: Disease associations with anti-neutrophil cytoplasmic antibodies. In Gross WL (ed), ANCA-Associated Vasculitides: Immunological and Clinical Aspects. New York: Plenum Press, 1993, pp 145-155.
39. Falk RJ, Terrell RS, Charles LA, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115-4119, 1990.
40. Abbott F, Jones S, Lockwood CM, Rees AJ: Autoantibodies to glomerular antigens in patients with Wegener's granulomatosis. Nephrol Dial Transplant 4:1-8, 1989.
41. Csemok E, Ludemann J, Gross WL, Bainton DF: Ultrastructural localisation of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol 137:1113-1120, 1990.
42. Keogan MT, Esnault VLM, Green AJ, Lockwood CM, Brown DL: Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 90:228-234, 1992.
43. Mulder AHL, Heeringa P, Brouwer E, Limburg PC, Kallenberg CGM: Activation of granulocytes by antineutrophil cytoplasmic antibodies (ANCA): a FcgRII-dependent process. Clin Exp Immunol 98:270-278, 1994.
44. Brouwer E, Cohen Tervaert JW, Horst G, et al: Predominance of IgG1 and IgG4 subclasses of antineutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 83:379-386, 1991.
45. Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD: Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells. Am J Pathol 141:335-342, 1992.
46. Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 41:375-383, 1992.
47. Deguchi Y, Shibata N, Kishimoto S: Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 81:311-314, 1990.
48. Pinching AJ, Rees AJ, Pussell BA, Lockwood CM, Mitchison RS, Peters DK: Relapses in Wegener's granulomatosis: the role of infection. Br Med J 281:836-838, 1980.
49. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 120:12-17, 1994.
50. Rieken B, Gutfleish J, Schlesier M, Peter HH: Impaired granulocyte oxidative burst and decreased expression of leucocyte adhesion molecule-1 (LAM-1) in patients with Wegener's granulomatosis. Clin Exp Immunol 96:43-47, 1994.
51. Mayet WJ, Meyer zum Buschenfelde KH: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 94:440-446, 1993.
52. Pall AA, Adu D, Drayson M, Taylor CM, Richards NT, Michael J: Circulating soluble adhesion molecules in systemic vasculitis. Nephrol Dial Transplant 9:770-774, 1994.
53. van de Weil BA, Dolman KM, van de Meer-Gerritsen CH, Hack CE, von de Borne AEG, Goldschmeding R: Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 90:409-414, 1992.
54. Daouk GH, Palsson R, Amin Arnaout M: Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int 47:1528-1536, 1995.
55. Savage COS, Gaskin G, Pusey CD, Pearson JD: Anti-neutrophil cytoplasmic antibodies (ANCA) can recognize vascular endothelial cell-bound ANCA-associated autoantigens. J Exp Nephrol 1:190-195, 1993.
56. Vargunam M, Adu D, Taylor CM, et al: Endothelium myeloperoxidase-antimyeloperoxidase interaction in vasculitis. Nephrol Dial Transplant 7:1077-1081, 1992.
57. Mayet WJ, Csernok E, Szymkowiak C, Gross WL, Meyer zum Buschenfelde KH: Human endothelial cells express proteinase 3 the target autoantigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 82:1221-1229, 1993.
58. King WJ, Adu D, Daha MR, et al: Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. Clin Exp Immunol 102:98-105, 1995.
59. Mayet WJ, Schwarting A, Meyer zum Buschenfelde KH: Cytotoxic effect of antibodies to proteinase 3 (cANCA) on human endothelial cells. Clin Exp Immunol 97:458-465, 1994.
60. Bolton WK, Innes D, Sturgill BC, Kaiser DL: T cells and macrophages in rapidly progressive glomerulonephritis: clinicopathoiogical correlates Kidney Int 32:869-876, 1987.
61. Muller GA, Muller CA, Markovic-Lipkovski J, Kilper RB, Risler T: Renal, major histocompatibility complex antigens and cellular components in rapidly progressive glomerulonephritis identified by monoclonal antibodies. Nephron 49:132-139, 1988.
62. Stegeman CA, Cohen Tervaert JW, Huitema MG, Kallenberg CGM: Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 91:415-420, 1993.
63. Schmitt WH, Heeson C, Csernok E, Rautmann A, Gross WL: Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthritis Rheum 35:1088-1096, 1992.
64. Lockwood CM, Stewart S, Thiru S, Isaacs JD, Hale G, Waldmann H: Humanised monoclonal antibody therapy for Wegener's granulomatosis. Clin Exp Immunol 101(suppl 1):43 (abstract), 1995.
65. Hagen EC, de Keizer RJ, Andrassy K, et al: Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 43:351-359, 1995.
66. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CGM: T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 98:448-453, 1994.
67. Ballieux BEPB, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJM, Daha MR: Cell mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 100:186-193, 1995.
68. Van de Woude FJ. van Es LA, Daha MR: The role of the cANCA antigen in the pathogenesis of Wegener's granulomatosis: a hypothesis based on both humoral and cellular mechanisms. Neth J Med 36:169-171, 1990.
69. Mathieson PW, Lockwood CM, Oliviera DGB: T and B cell responses to cytoplasmic antigens in systemic vasculitis. Clin Immunol Immunopathol 63:135-141, 1992.
70. Griffith ME, Coulthart A, Pusey CD: T cell responses to myeloperoxidase and proteinase 3 in systemic vasculitis. Clin Exp Immunol 103:253-258, 1995.
71. 2 in the rat, its possible role in an experimental autoimmune disease. Eur J Immunol 12:620-625, 1982:
72. Pelletier L, Pasquier R, Vial MOC: Mercury-induced autoimmune glomerulonephritis: requirement for T cells. Nephrol Dial Transplant 1:211-218, 1987.
73. 2 in the rat. J Immunol 126:699-702, 1981.
74. Pusey CD, Bowman C, Morgan A, Wheetman AP, Hartley B, Lockwood CM: Kinetics and pathogenicity of autoantibodies induced by mercuric chloride in the Brown Norway rat. Clin Exp Immunol 81:76-82, 1990.
75. Esnault VLM, Mathieson PW, Thiru S, Oliviera DBG, Lockwood CM: Autoantibodies to myeloperoxidase in Brown Norway rats treated with mercuric chloride. Lab Invest 67:114-120, 1992.
76. Mathieson PW, Thiru S, Oliviera DBG: Mercuric chloride-treated Brown Norway rats develop widespread tissue injury including necrotizing vasculitis. Lab Invest 67:121-129, 1992.
77. Kinjoh K, Kyogoku M, Good RA: Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc Natl Acad Sci USA 90:3413-3417, 1993.
78. Kinjoh K, Good RA, Taylor J. Nachman P, Falk RJ, Jennette JC: Hybridomas from SCG/Kj mice produce p-ANCA with specificity for myeloperoxidase (MPO) and induce proteinuria in nude mice. Clin Exp Immunol 101(suppl 1):37, 1995.
79. Brouwer E, Huitema MG, Klok P, et al: Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med 177:905-914, 1993.
80. Mrowka Ch, Csernok E, Bandel R, Handt St, Gross WL, Sieberth HG: An animal model of anti-PR3-associated glomerulonephritis - first results. Clin Exp Immunol 101(suppl 1):37, 1995.
81. Blank M, Tomer Y, Stein M, et al: Immunisation with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol 102: 120-130, 1995.
82. Fauci AS, Haynes BF, Katz P: The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 89(part 1):660-676, 1978.
83. Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301:235-238, 1979.
84. Fauci AS, Haynes BF, Katz P, Wolff S: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients over 21 years. Ann Intern Med 98:76-85, 1983.
85. Reza MJ, Dornfield L, Goldberg LS, Bluestone R, Pearson CM: Wegener's granulomatosis, long-term follow up of patients treated with cyclophosphamide. Arthritis Rheum 18:501-506, 1975.
86. Fuiano G, Cameron JS, Raftery M, Hartley BH, Williams DG, Ogg CS: Improved prognosis of renal microscopic polyarteritis in recent years. Nephrol Dial Transplant 3:383-391, 1988.
87. Falk RJ, Hogan S, Carey TS, Jennette JC: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 113:656-663, 1990.
88. Cohen J, Pinching AJ, Rees AJ, Peters DK: Infection and immunosuppression: a study of the infective complications of 75 patients with immunologically-mediated renal disease. Q J Med 51:1-15, 1982.
89. Haubitz M, Brunkhorst R, Schellong S, Gobel U, Schurek HJ, Koch KM: A prospective randomised study comparing daily oral versus monthly i.v. cyclophosphamide application in patients with ANCA-associated vasculitis and renal involvement. Clin Exp Immunol, 101(suppl):43 (abstract), 1995.
90. Glockner W, Sieberth HG, Wichmann HE, et al: Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled multi-centre study. Clin Nephrol 29:1-88, 1988.
91. Cole E, Cattran D, Magil A, et al: A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. Am J Kid Dis 20:261-269, 1992.
92. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 40:757-763, 1991.
93. Szpirt W, Rasmussen N, Thomsen B: Plasma exchange in patients with anti-neutrophil cytoplasm anti-bodies (ANCA) and acute renal failure. APMIS 19(suppl):63, 1990.
94. Levy JB, Winearls CG: Rapidly progressive glomerulonephritis: what should be first-line therapy? Nephron 67:402-407, 1994.
95. Pohl M, Lan S, Berl T, Lupus Nephritis Collaborative Study Group: Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. Ann Intern Med 114:924-929, 1991.
96. Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 9:368-375, 1989.
97. Bolton WK, Couser WG: Intravenous pulse methylprednisolone therapy of acute crescentic rapidly progressive glomerulonephritis. Am J Med 66:495-502, 1979.
98. Adu D, Howie AJ, Scott DGI, Bacon PA, McGonigle RJS, Michael J: Polyarteritis and the kidney. Q J Med 62:221-237, 1987.
99. Palmer A, Cairns T, Dische F, et al: Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 6:536-542, 1991.
100. Hartmann A, Nordal KP, Svennevig J, et al: Successful use of artificial lung (ECMO) and kidney in the treatment of a 20-year-old female with Wegener's syndrome. Nephrol Dial Transplant 9:316-319, 1994.
101. Hirschi RB, Pranikoff T, Gauger P, Schreiner RJ, Rechert R, Bartlett RH: Liquid ventilation in adults, children and full-term neonates. Lancet 346:1201-1202, 1995.
102. Gordon M, Luqmani RA, Adu D, et al: Relapses in patients with a systemic vasculitis. Q J Med 86:779-789, 1993.
103. Gaskin G, Pusey CD: Evolution of a policy to prevent vasculitis relapse. Clin Exp Immunol 101(suppl):46, 1995.
104. DeRemee RA, McDonald TJ: Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 60:27-32, 1985
105. Leavitt RY, Hoffman GS, Fauci AS: Response; the role of trimethoprim/sulphamethoxazole in the treatment of Wegener's granulomatosis. Arthritis Rheum 31:1073-1074, 1988.
106. DeRemee RA: The treatment of Wegener's granulomatosis with trimethoprim/sulphamethoxazole: illusion or vision? Arthritis Rheum 8:1068-1072, 1988.
107. Israel HL: Sulphamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 148:2293-2295, 1988.
108. Reinhold-Keller E, Beigel A, Duncker G, Heller M, Gross WL: Trimethoprim-sulphamethoxazole (T/S) in the long-term treatment of Wegener's granulomatosis. Clin Exp Immunol 93(suppl 1):38 (abstract), 1993.
109. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallebberg CGM: Prevention of relapses of Wegener's granulomatosis by treatment with trimethoprim-sulphamethoxazole: a multi-center placebo controlled trial in 81 patients. Clin Exp Immunol 101(suppl 1):44, 1995.
110. Jordon SC, Toyoda M: Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 97(suppl 1):31-38, 1994.
111. Jayne DR, Lockwood CM: Pooled IVIG in the management of SV. Adv Exp Med Biol 336:469-472, 1993.
112. Jayne DRW, Lockwood CM: Intravenous immunoglobulin alone for previously untreated vasculitis. Clin Exp Immunol (abstract), 101(suppl 1):46, 1995.
113. Pall AA, Varagunam M, Adu D. et al: Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin. Clin Exp Immunol 95:257-262, 1994.
114. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35:1322-1329, 1992.
115. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisolone. Arthritis Rheum 38:608-613, 1995.
116. Gremmel F, Druml W, Schmidt P, Graninger W: Cyclosporin in Wegener's granulomatosis. Ann Intern Med 108:491, 1988.
117. Borleffs JCC, Derksen RHWN, Hene RJ: Treatment of Wegener's granulomatosis with cyclosporin. Ann Rheum Dis 46:175, 1987.
118. Turney JH, Adu D, Michael J, McMaster P: Recurrent crescentic glomerulonephritis in renal transplant recipient treated with cyclosporin. Lancet 1:1104, 1986.
119. Schmitt WH, Haubitz M, Mistry N, Brunkhorst R, Erbsloh-Moller B, Gross WL: Renal Transplantation in Wegener's granulomatosis (letter). Lancet 342:860, 1993.